Filing Details
- Accession Number:
- 0001209191-21-038978
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-06-08 17:10:48
- Reporting Period:
- 2021-06-07
- Accepted Time:
- 2021-06-08 17:10:48
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1714899 | Denali Therapeutics Inc. | DNLI | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1437435 | Marc Tessier-Lavigne | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-06-07 | 39,303 | $18.00 | 2,583,673 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-06-07 | 27,830 | $18.92 | 2,611,503 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-06-07 | 27,245 | $19.50 | 2,638,748 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-06-07 | 93,678 | $70.35 | 2,545,070 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-06-07 | 700 | $71.06 | 2,544,370 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2021-06-07 | 39,303 | $0.00 | 39,303 | $18.00 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-06-07 | 27,830 | $0.00 | 27,830 | $18.92 |
| Common Stock | Stock Option (right to buy) | Disposition | 2021-06-07 | 27,245 | $0.00 | 27,245 | $19.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 7,862 | 2027-12-07 | No | 4 | M | Direct | |
| 0 | 2028-06-13 | No | 4 | M | Direct | |
| 0 | 2029-05-30 | No | 4 | M | Direct |
Footnotes
- Includes 2,074 restricted stock units.
- The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $70.00 to $70.965 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.02 to $71.07 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- 25% of the shares subject to the option vested on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.
- 100% of the shares subject to the option were fully vested and exercisable.
Billionaire Hedge Funds
